Figure 1From: Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study Physicians' (a) and patients' (b) assessmentsa of disease activity and individual symptoms over the study. aGlobal disease activity and symptoms were assessed by using a 5-point scale. *n = 33 for end of part 1.Back to article page